Vir Biotechnology (VIR) Projected to Post Earnings on Wednesday

Vir Biotechnology (NASDAQ:VIR) is projected to announce its earnings results after the market closes on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.85) per share and revenue of $8.14 million for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Vir Biotechnology Price Performance

Shares of NASDAQ VIR opened at $9.47 on Tuesday. The stock has a market capitalization of $1.30 billion, a PE ratio of -2.42 and a beta of 0.64. The business has a fifty day moving average price of $9.35 and a two-hundred day moving average price of $8.49. Vir Biotechnology has a fifty-two week low of $6.56 and a fifty-two week high of $14.45.

Analysts Set New Price Targets

Several equities analysts have weighed in on VIR shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Vir Biotechnology in a report on Wednesday, November 20th. JPMorgan Chase & Co. lifted their price objective on Vir Biotechnology from $10.00 to $14.00 and gave the company a “neutral” rating in a report on Thursday, January 9th. Morgan Stanley raised Vir Biotechnology from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $10.00 to $20.00 in a report on Thursday, January 9th. HC Wainwright reissued a “buy” rating and set a $110.00 price target on shares of Vir Biotechnology in a report on Friday, January 31st. Finally, Barclays lowered their price target on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Monday, November 4th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $34.83.

Insider Transactions at Vir Biotechnology

In other Vir Biotechnology news, Director George A. Scangos sold 10,964 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $9.81, for a total value of $107,556.84. Following the transaction, the director now owns 708,295 shares in the company, valued at approximately $6,948,373.95. This represents a 1.52 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Vicki L. Sato sold 10,960 shares of the stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $12.52, for a total value of $137,219.20. Following the completion of the transaction, the director now owns 1,312,391 shares in the company, valued at approximately $16,431,135.32. The trade was a 0.83 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 23,562 shares of company stock valued at $259,693. Corporate insiders own 15.60% of the company’s stock.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).